Leuprorelin

Leuprorelin

Clinical data
Pregnancy category	X
Routes of administration	Implant / Injection
ATC code	L02AE02 (WHO)
Legal status
Legal status	℞-only
Pharmacokinetic data
Elimination half-life	3 hours
Excretion	Renal
Identifiers
IUPAC name N-[1-[[1-[[1-[[1-[[1-[[1-[[5- (diaminomethylideneamino)-1- [2-(ethylcarbamoyl)pyrrolidin-1-yl]- 1-oxo-pentan-2-yl]carbamoyl]- 3-methyl-butyl]carbamoyl]-3-methyl- butyl]carbamoyl]-2-(4-hydroxyphenyl) ethyl]carbamoyl]-2-hydroxy-ethyl] carbamoyl]-2-(1H-indol-3-yl)ethyl] carbamoyl]-2-(3H-imidazol-4-yl)ethyl]- 5-oxo-pyrrolidine-2-carboxamide
CAS Number	53714-56-0
PubChem CID	441410
DrugBank	BTD00009
CompTox Dashboard (EPA)	DTXSID50872411
ECHA InfoCard	100.161.466
Chemical and physical data
Formula	C59H84N16O12
Molar mass	1209.4 g/mol g·mol−1

File:Leuprolide.gif

Lupron Logo

Leuprolide/Leuprorelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it initially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF. It is also considered a possible treatment for paraphilias. [1]

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron. It is available as a slow-release implant or sub-cutaneous/intramuscular injection.

External links

• Lupron Depot (manufacturer's website)
• Lupron® Injection (package insert from abbott)
• Trandolapril (patient information)